Pan-cancer analysis and verification revealed the clinical significance of SLC9A3R1 in bladder cancer cohort

Background Emerging evidence indicates that SLC9A3R1 participates in oncogenesis, yet its prognostic relevance and immune-regulatory circuitry remain largely undefined. Methods A harmonized pan-cancer transcriptomic compendium was retrieved from public repositories, and the clinical cohort was employed for bladder-cancer validation of expression patterns and biological function. Cox regression models were constructed to quantify the prognostic impact of SLC9A3R1, while immunohistochemistry on paired tumor and adjacent urothelium was performed to corroborate protein abundance and clinicopathological associations. Oncogenic and immunological roles were subsequently interrogated using R v4.2.1 and associated bioinformatics packages. Results Pan-cancer profiling demonstrated widespread SLC9A3R1 dysregulation that correlated with patient outcome across malignancies. Moreover, its expression aligned with genomic-heterogeneity indices and stemness scores in multiple tumor entities. Immunohistochemistry confirmed elevated SLC9A3R1 protein in bladder tumors, and, within the same cohort, transcript abundance paralleled tumor-associated fibroblast distribution.SLC9A3R1 up-regulation sustains stem-like traits, migration, chemoresistance and immune escape, driving bladder-cancer aggressiveness. Conclusion SLC9A3R1 constitutes a multi-dimensional prognostic biomarker that integrates tumor progression, immune contexture and patient survival, thereby offering a rational target for precision oncology.